UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice

Journal of hepatology, 2018-09, Vol.69 (3), p.676-686

2018

Link zum Volltext

Verfügbarkeit prüfen

Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study

Hepatology communications, 2022-09, Vol.6 (9), p.2379-2390

2022

Link zum Volltext

Verfügbarkeit prüfen

Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency

Metabolites, 2022-10, Vol.12 (10), p.952

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study

Hepatology communications, 2021-03, Vol.5 (3), p.478-490

2021

Link zum Volltext

Verfügbarkeit prüfen

The Critical Role of Chemokine (C-C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis

Frontiers in immunology, 2018-08, Vol.9, p.1852-1852

2018

Link zum Volltext

Verfügbarkeit prüfen

P142: Efficacy, safety and tolerability of chenodeoxycholic acid in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized, placebo-controlled phase 3 study

Genetics in Medicine Open, 2024, Vol.2, p.101039, Article 101039

2024

Link zum Volltext

Verfügbarkeit prüfen

The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice

Hepatology (Baltimore, Md.), 2006-02, Vol.43 (2), p.316-324

2006

Link zum Volltext

Verfügbarkeit prüfen

Hepatic stem cells

The Journal of pathology, 2002-07, Vol.197 (4), p.510-518

2002

Link zum Volltext

Verfügbarkeit prüfen

Dosing ileal bile acid transporter inhibitors in the fasted state minimizes gastrointestinal adverse effects while maintaining pharmacodynamic effect

Journal of hepatology, 2022-07, Vol.77, p.S599

2022

Link zum Volltext

Verfügbarkeit prüfen

THU-094 Clinical benefits with maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study

Journal of hepatology, 2024-06, Vol.80, p.S307-S307

2024

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol‐Induced Liver Damage, Steatosis, and Inflammation in Mice

Hepatology (Baltimore, Md.), 2019-03, Vol.69 (3), p.1105-1121

2019

Link zum Volltext

Verfügbarkeit prüfen

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Hepatology (Baltimore, Md.), 2018-05, Vol.67 (5), p.1754-1767

2018

Link zum Volltext

Verfügbarkeit prüfen

WED-252 - Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Journal of hepatology, 2023-06, Vol.78, p.S370-S370

2023

Link zum Volltext

Verfügbarkeit prüfen

Maralixibat leads to significant reductions in bilirubin for patients with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Journal of hepatology, 2023-06, Vol.78, p.S61

2023

Link zum Volltext

Verfügbarkeit prüfen

WED-257 - Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome

Journal of hepatology, 2023-06, Vol.78, p.S372-S372

2023

Link zum Volltext

Verfügbarkeit prüfen

Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome

Journal of hepatology, 2023-06, Vol.78, p.S372

2023

Link zum Volltext

Verfügbarkeit prüfen

Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Journal of hepatology, 2023-06, Vol.78, p.S370

2023

Link zum Volltext

Verfügbarkeit prüfen

OS-072 - Maralixibat leads to significant reductions in bilirubin for patients with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Journal of hepatology, 2023-06, Vol.78, p.S61-S61

2023

Link zum Volltext

Verfügbarkeit prüfen

Differential expression of bile acid subspecies with maralixibat treatment in pruritus responders with bile salt export pump deficiency

Journal of hepatology, 2020-08, Vol.73, p.S547

2020

Link zum Volltext

Verfügbarkeit prüfen

FRI296 - Differential expression of bile acid subspecies with maralixibat treatment in pruritus responders with bile salt export pump deficiency

Journal of hepatology, 2020-08, Vol.73, p.S547-S547

2020

Link zum Volltext

Verfügbarkeit prüfen

Psychometric evaluation of the adult itch reported outcome tool, a worst-itch numeric rating scale in adults with cholestatic liver disease

Journal of hepatology, 2020-08, Vol.73, p.S463

2020

Link zum Volltext

Verfügbarkeit prüfen

FRI131 - Psychometric evaluation of the adult itch reported outcome tool, a worst-itch numeric rating scale in adults with cholestatic liver disease

Journal of hepatology, 2020-08, Vol.73, p.S463-S463

2020

Link zum Volltext

Verfügbarkeit prüfen

THU-158 Improvements in serum bile acid levels are associated with improvements in key markers of liver health after maralixibat treatment in children with progressive familial intrahepatic cholestasis: data from the MARCH/MARCH-ON trials

Journal of hepatology, 2024-06, Vol.80, p.S331-S331

2024

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study

The Lancet (British edition), 2021-10, Vol.398 (10311), p.1581-1592

2021

Link zum Volltext

Verfügbarkeit prüfen

THU-129 Maralixibat improves growth in patients with progressive familial intrahepatic cholestasis: data from the MARCH/MARCH-ON trials

Journal of hepatology, 2024-06, Vol.80, p.S323-S324

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(54)
Dissertationen
(1)

Sprache

Englisch
(55)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice

Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study

Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency

Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study

The Critical Role of Chemokine (C-C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis

P142: Efficacy, safety and tolerability of chenodeoxycholic acid in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized, placebo-controlled phase 3 study

The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice

Hepatic stem cells

Dosing ileal bile acid transporter inhibitors in the fasted state minimizes gastrointestinal adverse effects while maintaining pharmacodynamic effect

THU-094 Clinical benefits with maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study

Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol‐Induced Liver Damage, Steatosis, and Inflammation in Mice

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

WED-252 - Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Maralixibat leads to significant reductions in bilirubin for patients with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

WED-257 - Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome

Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome

Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

OS-072 - Maralixibat leads to significant reductions in bilirubin for patients with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Differential expression of bile acid subspecies with maralixibat treatment in pruritus responders with bile salt export pump deficiency

FRI296 - Differential expression of bile acid subspecies with maralixibat treatment in pruritus responders with bile salt export pump deficiency

Psychometric evaluation of the adult itch reported outcome tool, a worst-itch numeric rating scale in adults with cholestatic liver disease

FRI131 - Psychometric evaluation of the adult itch reported outcome tool, a worst-itch numeric rating scale in adults with cholestatic liver disease

THU-158 Improvements in serum bile acid levels are associated with improvements in key markers of liver health after maralixibat treatment in children with progressive familial intrahepatic cholestasis: data from the MARCH/MARCH-ON trials

Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study

THU-129 Maralixibat improves growth in patients with progressive familial intrahepatic cholestasis: data from the MARCH/MARCH-ON trials

Suchergebnisse filtern